Shares of TransEnterix, Inc. (NYSEAMERICAN:TRXC) gapped up before the market opened on Wednesday . The stock had previously closed at $2.68, but opened at $2.58. TransEnterix shares last traded at $2.84, with a volume of 180193 shares traded.
A number of research firms have recently weighed in on TRXC. Zacks Investment Research raised TransEnterix from a “sell” rating to a “hold” rating in a research report on Tuesday, January 23rd. BTIG Research raised TransEnterix from a “neutral” rating to a “buy” rating in a research report on Wednesday, May 9th. Two investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $2.61.
TransEnterix (NYSEAMERICAN:TRXC) last issued its earnings results on Tuesday, May 8th. The medical instruments supplier reported ($0.06) EPS for the quarter, topping analysts’ consensus estimates of ($0.07) by $0.01. The firm had revenue of $4.77 million during the quarter, compared to the consensus estimate of $3.81 million. TransEnterix had a negative net margin of 21,045.36% and a negative return on equity of 137.69%.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. JPMorgan Chase & Co. boosted its stake in TransEnterix by 2.1% in the first quarter. JPMorgan Chase & Co. now owns 7,278,527 shares of the medical instruments supplier’s stock valued at $12,374,000 after acquiring an additional 151,921 shares in the last quarter. Redmile Group LLC purchased a new position in TransEnterix during the fourth quarter worth about $9,684,000. Millennium Management LLC raised its holdings in TransEnterix by 787.5% during the first quarter. Millennium Management LLC now owns 1,895,115 shares of the medical instruments supplier’s stock worth $3,222,000 after purchasing an additional 1,681,583 shares in the last quarter. BlackRock Inc. raised its holdings in TransEnterix by 157.3% during the fourth quarter. BlackRock Inc. now owns 1,760,266 shares of the medical instruments supplier’s stock worth $3,397,000 after purchasing an additional 1,076,133 shares in the last quarter. Finally, UBS Group AG raised its holdings in TransEnterix by 1,658.3% during the first quarter. UBS Group AG now owns 906,280 shares of the medical instruments supplier’s stock worth $1,541,000 after purchasing an additional 854,737 shares in the last quarter.
TransEnterix Company Profile
TransEnterix, Inc, a medical device company, engages in the research, development, and sale of medical device robotics to enhance minimally invasive surgery. The company offers Senhance System, a multi-port robotic surgery system, which allows up to four arms to control robotic instruments and a camera in Europe.
Receive News & Ratings for TransEnterix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TransEnterix and related companies with MarketBeat.com's FREE daily email newsletter.